BCM
PACB icon

Bluefin Capital Management’s Pacific Biosciences PACB Stock Holding History

Bluefin Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-70,600
Closed -$18K – 608
2019
Q4 		$18K Buy
70,600
+600
+0.9% +$3.05K ﹤0.01% 507
2019
Q3 		$23K Buy
+70,000
New +$392K ﹤0.01% 425

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $290M AUM 183.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bluefin Capital Management's PACB Position: Q1 2020 in Review

Bluefin Capital Management sold out of Pacific Biosciences (PACB) in Q1 2020, closing a stake of 61,185 shares — an estimated $314K sold.

Bluefin Capital Management first reported a position in PACB in Q2 2019 and held it in 3 quarters. The position peaked at $314K in Q4 2019. 132 funds tracked by Wall St. Rank hold PACB as of Q1 2020.

  • Bluefin Capital Management reported no remaining Pacific Biosciences position as of Q1 2020 after selling out during the quarter.
  • Bluefin Capital Management sold 61,185 Pacific Biosciences shares in Q1 2020, an estimated $314K.
  • Bluefin Capital Management first reported a position in Pacific Biosciences in Q2 2019 and held it in 3 quarters.
  • Bluefin Capital Management's Pacific Biosciences position peaked at $314K in Q4 2019.
  • 132 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2020.

Based on Bluefin Capital Management's 13F filing for Q1 2020, filed 15 May 2020.